Retatrutide
Triple receptor activity at GLP-1, GIP and glucagon pathways. The reported Phase 2 result came from a defined dose and study population.
PEPTIDEATLAS / LIBRARY
Retatrutide vs survodutide: what the trials compare
Context for the mechanisms, trials and limits of comparing retatrutide and survodutide.
Why the percentages are not a ranking
Retatrutide and survodutide are investigational molecules studied in different programmes. A headline percentage cannot be compared without checking the dose, participants, duration, analysis and comparator.
Survodutide
Dual receptor activity at GLP-1 and glucagon pathways. Its trial results use a different programme, population and analysis plan.
What to check in a trial
- Who was enrolled and what conditions were included?
- What dose and treatment duration were studied?
- Was the result intention-to-treat, on-treatment or another analysis?
- What happened with adverse events and discontinuations?
- Was the comparator placebo or another medicine?
Continue to the evidence
See the clinical evidence cards, the latest research and regulatory updates, or compare external research catalogues.
This page is educational. Neither molecule is presented as an approved treatment, and clinical findings do not validate products sold through an online catalogue.